Apatinib Combined With PLD vs PLD for Platinum-resistant Recurrent Ovarian Cancer

NCT04348032 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

152

Enrollment

OTHER

Sponsor class

Conditions

Platinum-resistant Recurrent Ovarian Cancer

Interventions

DRUG: PLD 40mg/m2 ivgtt q4w +Apatinib 250mg po qd
DRUG: PLD 40mg/m2 ivgtt q4w

Sponsor

Chinese Academy of Medical Sciences

Collaborators

[object Object]